We review different antibody-based and immunotherapeutic approaches targeting CSPG4 in melanoma and discuss how such immune cell-targeting interventions could be refined to attain, enhance, prolong, or maintain clinical efficacy. The gene discussed is CSPG4; the disease is melanoma.